Adcetris (brentuximab vedotin)

June 6, 2019

Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals

News

Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated ... Read more

May 14, 2019

Health Canada Approves Adcetris-Chemo for Advanced Classical Hodgkin’s Lymphoma

News

Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. ... Read more

March 29, 2019

UK’s NICE Recommends Adcetris as Second-line Treatment for Certain CTCL Patients

News

After first rejecting it due to cost-effectiveness concerns, the National Institute for Health and Care Excellence (NICE) has now recommended the use of Adcetris (brentuximab vedotin) as a second-line therapy for patients with CD30-positive cutaneous T-cell ... Read more

November 27, 2018

Opdivo Halts Hodgkin’s Progression in Those Who Earlier Had Achieved Remission, Study Shows

News

Re-treatment with Opdivo (nivolumab) may be a safe and effective option to halt disease progression in patients with classical Hodgkin’s lymphoma (cHL) who previously achieved disease remission with the treatment, a ... Read more

October 3, 2018

Adcetris-Gemcitabine Combo Eliminates Cancer in Two-thirds of Hodgkin’s Lymphoma Patients in Phase 1/2 Trial

News

A combination of Adcetris (brentuximab vedotin) and the chemotherapy gemcitabine completely eliminated the tumors in two out of three children and young adults with Hodgkin’s lymphoma in a Phase 1/2 ... Read more

September 26, 2018

Adcetris, Chemo Combo Approved in Japan for Untreated, Advanced Hodgkin’s Lymphoma

News

The Japanese Ministry of Health, Labour and Welfare has approved the use of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for CD30-positive Hodgkin’s lymphoma patients ... Read more

September 24, 2018

Adcetris May Increase Risk of Lung Toxicity in Younger Hodgkin’s Lymphoma Patients, Study Suggests

News

Adcetris (brentuximab vedotin) treatment may increase the chances of lung toxicity in children and young adults with relapsed or refractory Hodgkin’s lymphoma, a small retrospective study suggests. The study, “Pulmonary ... Read more

June 27, 2018

Keytruda-AFM13 Combo Effective for Hodgkin’s Lymphoma, Preliminary Phase 1b Data Show

News

Treatment with Keytruda (pembrolizumab) and Affimed’s AFM13 is well-tolerated with a favorable response rate in patients with relapsed or refractory Hodgkin’s lymphoma, according to an early analysis of a Phase 1b trial. ... Read more

March 22, 2018

FDA Approves Adcetris, Chemotherapy Combo for Advanced Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration approved the combination of Seattle Genetics’ Adcetris (brentuximab vedotin) with chemotherapy for the treatment of adults with previously untreated stage 3 or 4 classical Hodgkin’s ... Read more

February 1, 2018February 1, 2018

Adcetris-Chemo Combo Delays Disease Progression in Newly-diagnosed Advanced Lymphoma, Trial Shows

News

Results from a Phase 3 clinical trial show that adding Adcetris (brentuximab vedotin) to a chemotherapy regimen reduces the risk of disease progression, death, or use of additional anticancer therapies for ... Read more